ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1244

PACFiND: Co-Designing Principles To Inform Reconfiguration Of Fibromyalgia Care Across Health Systems

Rosemary Hollick1, Marcus Beasley1, Ernest Choy2, Caroline Cupit3, Debra Dulake1, Teresa Finlay3, Louise Locock1, Paul McNamee1, Catherine Pope3, Elaine Wainwright1, David Williams4 and Gary Macfarlane1, 1University of Aberdeen, Aberdeen, United Kingdom, 2Division of Infection and Immunity, CREATE Centre, Cardiff University, Cardiff, United Kingdom, 3University of Oxford, Oxford, United Kingdom, 4University of Michigan, Michigan

Meeting: ACR Convergence 2025

Keywords: Access to care, fibromyalgia, Health Care, Health Services Research, quality of care

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: (1221–1247) Pain in Rheumatic Disease Including Fibromyalgia Poster

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Fibromyalgia is a contested and poorly supported condition, characterised by widespread pain, fatigue, and cognitive symptoms, often compounded by stigma and delayed diagnosis. Existing services are fragmented and inconsistent, with high patient and system burden. The PACFiND study (PAtient-centred Care for Fibromyalgia: New pathway Design) aimed to inform new models of care for fibromyalgia.

Methods: A mixed method design integrated systematic literature reviews, surveys of, and interviews with, people with fibromyalgia symptoms/diagnosis and healthcare professionals, analysis of routine healthcare data and service case studies, to explore care pathways for fibromyalgia in the UK. Data collection included over 2,700 survey responses from patients and professionals, 31 in-depth interviews, 12 UK-wide service case studies, and national healthcare data on nearly 100,000 individuals. Findings were synthesised through investigator meetings and structured workshops, involving patients, public representatives, clinicians, commissioners, and policymakers to co-design principles of care to inform new care models.

Results: Findings highlighted delayed and inconsistent approaches to diagnosis, especially in men, and limited post-diagnosis support. Many health professionals questioned the validity of a fibromyalgia diagnosis. Patients often faced a revolving door of referrals across specialties, particularly pain management, gastroenterology, and general surgery, and invasive investigations. They reported substantial out-of-pocket costs, difficulty navigating services, and poor work outcomes. Healthcare professionals expressed uncertainty in making a diagnosis and management, with variable understanding of fibromyalgia as a central sensitisation condition. While medication remains a default, patients voiced strong preferences for personalised, holistic, and non-pharmacological interventions, delivered with empathy and continuity. Community resources, such as support groups, play a key role but lack formal recognition. Insights informed evidence based care principles (Figure 1) and potential delivery across different settings. For example: (1) primary care e.g., family physicians for early recognition, supported by training; (2) specialist input for complex diagnosis and management; and (3) wraparound support, integrating physical, psychological, and peer-led services. These aim to reduce inappropriate referrals, improve experience and outcomes, and enable tailored, appropriate place-based care.

Conclusion: The PACFiND study has co-designed multilevel principles for fibromyalgia care aligned with patient needs and system priorities. While conducted in the UK, the challenges identified—delayed diagnosis, fragmented care, and unmet patient needs—are common across healthcare systems globally, including the US. Although the logistics of implementation may differ, the core principles of integrated, person-centred, and evidence-informed care are widely applicable. This model offers a flexible framework to guide service redesign internationally. Next steps include testing in implementation settings and using economic data to support scale-up.

Supporting image 1Figure 1. Evidence-based principles of care to guide fibromyalgia service redesign.


Disclosures: R. Hollick: None; M. Beasley: None; E. Choy: AbbVie, 2, 6, Alfasigma, 6, Bio-Cancer, 2, 5, Biocon, 2, Biogen, 2, 5, Chugai Pharma, 2, 6, Eli Lilly, 6, Fresenius Kabi, 2, 6, Gedeon Richter, 2, 6, Gilead, 2, Janssen, 2, 6, Pfizer, 2, 5, 6, Sanofi, 2, 5, 6, UCB, 2, 6, Viatris, 2, 6; C. Cupit: None; D. Dulake: None; T. Finlay: None; L. Locock: None; P. McNamee: None; C. Pope: None; E. Wainwright: None; D. Williams: None; G. Macfarlane: None.

To cite this abstract in AMA style:

Hollick R, Beasley M, Choy E, Cupit C, Dulake D, Finlay T, Locock L, McNamee P, Pope C, Wainwright E, Williams D, Macfarlane G. PACFiND: Co-Designing Principles To Inform Reconfiguration Of Fibromyalgia Care Across Health Systems [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/pacfind-co-designing-principles-to-inform-reconfiguration-of-fibromyalgia-care-across-health-systems/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/pacfind-co-designing-principles-to-inform-reconfiguration-of-fibromyalgia-care-across-health-systems/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology